On behalf of 28 former government officials, professors, & public interest advocates, Alex Moss and Prof. Michael Carrier urged the DOJ Antitrust Division to reconsider a business letter supporting the Avanci patent pool that targets the automotive industry. We explain that the letter 1) undermines bipartisan consensus, (2) relies on questionable positions, (3) expresses … Continue reading Prof. Michael Carrier & Alex Moss urge DOJ Antitrust Division to reconsider business review letter…
Category: Announcements
Prof. Michael Carrier to give lecture in Distinguished Speaker Series at St. Louis University
Prof. Michael Carrier will present his article “Three Challenges for Pharmaceutical Antitrust” as part of the Distinguished Speaker Series at St. Louis University on Thursday, Feb. 2. Available via Zoom! Register here: https://forms.gle/86sd2gkmZH8yw8TLA #HealthLaw
Prof. Michael Carrier to give talks at NY bar association and European University Institute
Prof. Michael Carrier will give talks at (1) the N.Y. State Bar Association on patent settlements and patent thickets and (2) the European University Institute on standard essential patents and an aspect of global litigation known as “anti-suit Injunctions.”
Professor Ellen P. Goodman’s work cited in FTC’s Report to Congress on “Combatting Online Harms Through Innovation”
RIIPL Co-Director, Professor Ellen P. Goodman’s work was cited in the Federal Trade Commission’s June 2022 Report to Congress on “Combatting Online Harms Through Innovation.” Congress called upon the FTC to report on how artificial intelligence could be used to address online harms in the 2021 Appropriation Act. In the report’s recommendations on platform … Continue reading Professor Ellen P. Goodman’s work cited in FTC’s Report to Congress on “Combatting Online Harms Through Innovation”…
Prof. Michael Carrier to give talk to state antitrust enforcers
Prof. Michael Carrier will give a talk to the antitrust section of the Pharmaceutical Industry Working Group for the National Association of Attorneys General. He will discuss leading issues relating to competition between biologic medicines and more affordable biosimilars.